(Eptinezumab)Biosimilar Reference Antibody-GS40237

货号：GS40237

Eptinezumab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody specifically approved for the preventive treatment of migraine in adults. It represents a targeted therapy within the class of calcitonin gene-related peptide (CGRP) pathway inhibitors. Eptinezumab functions as a highly selective CGRP antagonist, designed to bind and neutralize the CGRP ligand in the bloodstream. By blocking CGRP from interacting with its receptors, it aims to prevent the initiation and propagation of the neuroinflammatory cascade believed to underlie migraine attacks, thereby reducing migraine frequency and severity.